Posted inBiotechnology
Fierce Biotech Layoff Tracker 2025: CytomX cuts team by 40%
We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared…
Posted inBiotechnology
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis prospect
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found…
Posted inBiotechnology
Rapt re-rolls after flameout, paying $35M for challenger to Novartis, Roche drug
Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a…
Posted inBiotechnology
Sanofi pays SK bioscience €50M as children’s pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine…
Posted inBiotechnology
Phase 2 data will drive biopharma VC investments next year: PitchBook
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into…
Posted inBiotechnology
Discover Astellas’ differentiated approach to innovation partnerships
As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. If you are…
Posted inBiotechnology
Galectin’s MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…
Posted inBiotechnology
Applied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuit
A turbulent month at Applied Therapeutics is being capped off with the departure of CEO and chair Shoshana Shendelman, Ph.D.,…
Posted inBiotechnology
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to…
Posted inBiotechnology
Apollomics, after giving up on GlycoMimetics’ leukemia therapy, posts drug’s latest phase 3 fail
The failure of a myeloid leukemia drug in a phase 3 trial in China isn’t a shock to Apollomics, which…